These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36777472)

  • 1. Effect of hydroxychloroquine on beta cell function, insulin resistance, and inflammatory markers in type 2 diabetes patients uncontrolled on glimepiride and metformin therapy.
    Rajput R; Upadhyay P; Rajput S; Saini S; Kharab S
    Int J Diabetes Dev Ctries; 2023 Feb; ():1-6. PubMed ID: 36777472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Hydroxychloroquine on Glycemic Variability in Type 2 Diabetes Patients Uncontrolled on Glimepiride and Metformin Therapy.
    Rajput R; Saini S; Rajput S; Upadhyay P
    Indian J Endocrinol Metab; 2022; 26(6):537-542. PubMed ID: 39005510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Clinical Effectiveness and Tolerability of Hydroxychloroquine 400 Mg in Uncontrolled Type 2 Diabetes Subjects who are not Willing to Initiate Insulin Therapy (HYQ-Real-World Study).
    Gupta A
    Curr Diabetes Rev; 2019; 15(6):510-519. PubMed ID: 31713476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs.
    Chakravarti HN; Nag A
    J Endocrinol Invest; 2021 Mar; 44(3):481-492. PubMed ID: 32594451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and Safety of Hydroxychloroquine compared to Teneligliptin in uncontrolled T2DM patients as add-on Therapy.
    Kumar A; Prakash AS
    J ASEAN Fed Endocr Soc; 2019; 34(1):87-91. PubMed ID: 33442141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease.
    Werida R; Kabel M; Omran G; Shokry A; Mostafa T
    Diabetes Res Clin Pract; 2020 Dec; 170():108473. PubMed ID: 33002553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of efficacy and tolerability of glimepiride and metformin combination: a multicentric study in patients with type-2 diabetes mellitus, uncontrolled on monotherapy with sulfonylurea or metformin.
    Pareek A; Chandurkar NB; Salkar HR; Borkar MS; Tiwari D
    Am J Ther; 2013 Jan; 20(1):41-7. PubMed ID: 21326082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
    Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
    Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
    Derosa G; Maffioli P; Ferrari I; Mereu R; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Salvadeo SA
    Horm Metab Res; 2010 Aug; 42(9):663-9. PubMed ID: 20560108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial.
    Wasko MC; McClure CK; Kelsey SF; Huber K; Orchard T; Toledo FG
    Diabetologia; 2015 Oct; 58(10):2336-43. PubMed ID: 26197707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study.
    Moon JS; Ha KS; Yoon JS; Lee HW; Lee HC; Won KC;
    Acta Diabetol; 2014 Apr; 51(2):277-85. PubMed ID: 24445656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride.
    Pfützner A; Schöndorf T; Seidel D; Winkler K; Matthaei S; Hamann A; Forst T
    Metabolism; 2006 Jan; 55(1):20-5. PubMed ID: 16324915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes.
    Derosa G; Bonaventura A; Bianchi L; Romano D; Fogari E; D'Angelo A; Maffioli P
    Diabet Med; 2014 Dec; 31(12):1515-23. PubMed ID: 24824633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between the therapeutic effect of metformin, glimepiride and their combination as an add-on treatment to insulin glargine in uncontrolled patients with type 2 diabetes.
    Park CY; Kang JG; Chon S; Noh J; Oh SJ; Lee CB; Park SW
    PLoS One; 2014; 9(3):e87799. PubMed ID: 24614911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone.
    Pareek A; Chandurkar N; Thomas N; Viswanathan V; Deshpande A; Gupta OP; Shah A; Kakrani A; Bhandari S; Thulasidharan NK; Saboo B; Devaramani S; Vijaykumar NB; Sharma S; Agrawal N; Mahesh M; Kothari K
    Curr Med Res Opin; 2014 Jul; 30(7):1257-66. PubMed ID: 24669876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
    Kadoglou NP; Kapelouzou A; Tsanikidis H; Vitta I; Liapis CD; Sailer N
    Exp Clin Endocrinol Diabetes; 2011 Feb; 119(2):63-8. PubMed ID: 21031343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
    Sjöstrand M; Iqbal N; Lu J; Hirshberg B
    Diabetes Res Clin Pract; 2014 Aug; 105(2):185-91. PubMed ID: 24947443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin plus low-dose glimeperide significantly improves Homeostasis Model Assessment for insulin resistance (HOMA(IR)) and beta-cell function (HOMA(beta-cell)) without hyperinsulinemia in patients with type 2 diabetes mellitus.
    Bermúdez-Pirela VJ; Cano C; Medina MT; Souki A; Lemus MA; Leal EM; Seyfi HA; Cano R; Ciscek A; Bermúdez-Arias F; Contreras F; Israili ZH; Hernández-Hernández R; Valasco M
    Am J Ther; 2007; 14(2):194-202. PubMed ID: 17414590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients.
    Derosa G; Putignano P; Bossi AC; Bonaventura A; Querci F; Franzetti IG; Guazzini B; Testori G; Fogari E; Maffioli P
    Eur J Pharmacol; 2011 Sep; 666(1-3):251-6. PubMed ID: 21645507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.